250 related articles for article (PubMed ID: 24634022)
1. The cost effectiveness of ivabradine in the treatment of chronic heart failure from the U.K. National Health Service perspective.
Griffiths A; Paracha N; Davies A; Branscombe N; Cowie MR; Sculpher M
Heart; 2014 Jul; 100(13):1031-6. PubMed ID: 24634022
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Ivabradine for Heart Failure in the United States.
Kansal AR; Cowie MR; Kielhorn A; Krotneva S; Tafazzoli A; Zheng Y; Yurgin N
J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27153871
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece.
Kourlaba G; Parissis J; Karavidas A; Beletsi A; Milonas C; Branscombe N; Maniadakis N
BMC Health Serv Res; 2014 Dec; 14():631. PubMed ID: 25496716
[TBL] [Abstract][Full Text] [Related]
4. [Cost-effectiveness and budget impact of ivabradine in heart failure therapy].
Polistena B; Maggioni AP; Oliva F; Spandonaro F
G Ital Cardiol (Rome); 2014 Nov; 15(11):626-33. PubMed ID: 25424141
[TBL] [Abstract][Full Text] [Related]
5. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study.
Böhm M; Borer J; Ford I; Gonzalez-Juanatey JR; Komajda M; Lopez-Sendon J; Reil JC; Swedberg K; Tavazzi L
Clin Res Cardiol; 2013 Jan; 102(1):11-22. PubMed ID: 22575988
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Ivabradine in the Treatment of Chronic Heart Failure.
Adena MA; Hamann G; Sindone AP
Heart Lung Circ; 2019 Mar; 28(3):414-422. PubMed ID: 29449079
[TBL] [Abstract][Full Text] [Related]
7. Ivabradine is cost-effective in the treatment of chronic heart failure.
Morris S; Hunter R
Heart; 2014 Jul; 100(13):991-2. PubMed ID: 24737656
[No Abstract] [Full Text] [Related]
8. Advances in the management of heart failure: the role of ivabradine.
Müller-Werdan U; Stöckl G; Werdan K
Vasc Health Risk Manag; 2016; 12():453-470. PubMed ID: 27895488
[TBL] [Abstract][Full Text] [Related]
9. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model.
Pufulete M; Maishman R; Dabner L; Mohiuddin S; Hollingworth W; Rogers CA; Higgins J; Dayer M; Macleod J; Purdy S; McDonagh T; Nightingale A; Williams R; Reeves BC
Health Technol Assess; 2017 Aug; 21(40):1-150. PubMed ID: 28774374
[TBL] [Abstract][Full Text] [Related]
11. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
12. Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model.
Sutcliffe P; Connock M; Pulikottil-Jacob R; Kandala NB; Suri G; Gurung T; Grove A; Shyangdan D; Briscoe S; Maheswaran H; Clarke A
Health Technol Assess; 2013 Nov; 17(53):1-499, v-vi. PubMed ID: 24280231
[TBL] [Abstract][Full Text] [Related]
13. The cost effectiveness of REACH-HF and home-based cardiac rehabilitation compared with the usual medical care for heart failure with reduced ejection fraction: A decision model-based analysis.
Taylor RS; Sadler S; Dalal HM; Warren FC; Jolly K; Davis RC; Doherty P; Miles J; Greaves C; Wingham J; Hillsdon M; Abraham C; Frost J; Singh S; Hayward C; Eyre V; Paul K; Lang CC; Smith K
Eur J Prev Cardiol; 2019 Aug; 26(12):1252-1261. PubMed ID: 30884975
[TBL] [Abstract][Full Text] [Related]
14. Economic Evaluation of Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure With Reduced Ejection Fraction.
Chew DS; Loring Z; Anand J; Fudim M; Lowenstern A; Rymer JA; Weimer KED; Atwater BD; DeVore AD; Exner DV; Noseworthy PA; Yancy CW; Mark DB; Piccini JP
Circ Cardiovasc Qual Outcomes; 2020 Dec; 13(12):e007094. PubMed ID: 33280436
[TBL] [Abstract][Full Text] [Related]
15. Cost-Utility of Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure: An Economic Evaluation.
Lau D; Sandhu RK; Andrade JG; Ezekowitz J; So H; Klarenbach S
J Am Heart Assoc; 2021 Jul; 10(14):e019599. PubMed ID: 34238020
[TBL] [Abstract][Full Text] [Related]
16. COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN TREATMENT OF PATIENTS WITH HEART FAILURE IN IRAN.
Taheri S; Heidari E; Aivazi MA; Shams-Beyranvand M; Varmaghani M
Int J Technol Assess Health Care; 2018; 34(6):576-583. PubMed ID: 30560749
[TBL] [Abstract][Full Text] [Related]
17. Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States.
Borer JS; Kansal AR; Dorman ED; Krotneva S; Zheng Y; Patel HK; Tavazzi L; Komajda M; Ford I; Böhm M; Kielhorn A
J Manag Care Spec Pharm; 2016 Sep; 22(9):1064-71. PubMed ID: 27579829
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
19. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
